Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 44,917 shares of the stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $246.32, for a total transaction of $11,063,955.44. Following the completion of the transaction, the chief operating officer directly owned 71,602 shares of the company's stock, valued at $17,637,004.64. This trade represents a 38.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Glaukos Price Performance
Shares of Glaukos stock traded down $0.69 during midday trading on Monday, hitting $245.03. 848,336 shares of the company were exchanged, compared to its average volume of 1,924,346. The firm has a 50 day simple moving average of $185.95 and a 200-day simple moving average of $147.70. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. Glaukos Corporation has a 52 week low of $87.32 and a 52 week high of $255.18.
Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.57. The firm had revenue of $211.03 million for the quarter, compared to analysts' expectations of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The business's revenue was up 58.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) earnings per share. As a group, sell-side analysts anticipate that Glaukos Corporation will post 0.50 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have commented on GKOS shares. Weiss Ratings restated a "sell (d-)" rating on shares of Glaukos in a research report on Thursday, October 15th. HC Wainwright raised their price objective on shares of Glaukos from $195.00 to $248.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. Mizuho set a $225.00 price objective on shares of Glaukos in a report on Thursday, October 29th. Zacks Research upgraded shares of Glaukos from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 28th. Finally, UBS Group initiated coverage on Glaukos in a report on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus target price of $218.00.
Get Our Latest Stock Analysis on Glaukos
Institutional Investors Weigh In On Glaukos
Hedge funds and other institutional investors have recently made changes to their positions in the company. Soleus Capital Management L.P. bought a new position in Glaukos in the third quarter valued at about $4,195,000. Cetera Investment Advisers increased its position in Glaukos by 6.1% in the third quarter. Cetera Investment Advisers now owns 3,402 shares of the medical instruments supplier's stock worth $559,000 after purchasing an additional 197 shares during the period. Entropy Technologies LP acquired a new stake in Glaukos in the third quarter worth about $402,000. Jump Financial LLC bought a new stake in Glaukos during the 3rd quarter worth about $2,014,000. Finally, Pathstone Holdings LLC raised its holdings in Glaukos by 9.0% during the 3rd quarter. Pathstone Holdings LLC now owns 17,676 shares of the medical instruments supplier's stock worth $2,902,000 after purchasing an additional 1,462 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.